Home
overview
The development of controlled release systems has exacerbated the interest and importance of drug delivery issues in pharmaceutical R & D. Staying ahead in today’s highly competitive drug delivery market can be both time-consuming and costly, and the potential applications of controlled release are enormous, so keeping fully up to date with the latest developments is exceptionally important.

Controlled Release offers you the opportunity to fully explore this topic and stay abreast of the latest advancements in technology and drug delivery systems, enabling you to lead the field in this important area of drug development. The conference will address both established and new technologies involved in controlled release drug delivery systems, company development profiles and applications of controlled release strategies. Commercial issues such as regulatory, intellectual property and partnering issues will also be discussed. This top-level forum brings together experts in controlled release to offer valuable insights into the opportunities within this rapidly expanding market.

Why should you attend this event? This comprehensive conference is organised and produced by SMi: we have identified controlled release as an area that is important to executives eager to keep up to date with industry developments in this vital area. As a key industry representative, you are aware of the growing importance of developments that will increase both your efficiency and productivity. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Professor Alexander Florence

Professor Alexander Florence, Dean, School of Pharmacy, University of London

9:10 THE ROLE OF PHARMACOLOGY DISCOVERY IN DRUG DELIVERY

Dr Suneel Gupta

Dr Suneel Gupta, Vice President, Clinical Research and Pharmacology, ALZA

  • Factors essential for controlled release in humans
  • High therapeutic availability of controlled released drugs
  • Controlled release by diffusion, solvent-activated release or polymeric degradation
  • Increasing the drug value by controlling release
  • Patent position of controlled release drugs
  • Controlled release: the future for the patient
  • 9:40 ORAL CONTROLLED RELEASE

    Dr Ross MacRae

    Dr Ross MacRae, Manager, Pharmaceutical Research & Development, Pfizer

  • Enabling discovery programmes
  • Product enhancement
  • Applicability of ‘standard’ technologies
  • Insourcing vs outsourcing oral CR formulation development programmes
  • Future technology needs and aspirations
  • 10:20 PULMONARY FORMULATIONS

    Dr Sujit Basu

    Dr Sujit Basu, Staff Scientist, Alkermes

  • Inhaled drug delivery systems – an alternative to injections
  • Advantages of AIR porous particles for pulmonary drug delivery
  • Factors influencing controlled release in the lung
  • Achieving controlled release in the lung
  • The future: controlled release pulmonary drug delivery
  • 11:00 Morning Coffee

    11:20 POLYMERIC DRUG DELIVERY OR PARENTERAL SYSTEMS

    Dr Murat Acemoglu

    Dr Murat Acemoglu, , Novartis

  • Bulk erosion of polymer implants
  • Surface erosion of polymer implants
  • Chemical pathways of biodegradation
  • PEC as a surface eroding polymer
  • Mechanism of biodegradation of PEC
  • Applications for sustained parenteral delivery of drugs
  • 12:00 POLYSIALIC ACIDS IN DRUG DELIVERY

    Professor Gregory Gregoriadis

    Professor Gregory Gregoriadis, Professor / Science Director, School of Pharmacy, University of London / Lipoxen Technologies

  • Polysialic acids: characteristics and behaviour in vivo
  • Polysialylation of therapeutics
  • Reducing the antigenicity of protein drugs
  • Improving the stability of peptides and proteins
  • Improving the pharmacokinetics and activity of peptide and protein drugs
  • 12:40 Networking Lunch

    13:40 PROMAXX PROTEIN MICROSPHERES

    Dr Larry Brown

    Dr Larry Brown, Executive Director, Scientific Affairs, Epic Therapeutics

  • A novel protein based microsphere formulation has been developed that can be utilized in immediate or sustained release of pharmaceutical dosage forms
  • Studies will be presented using ProMaxx as an injectable or pulmonary dosage form
  • Microspheres are virtually all protein
  • Microspheres formed in a totally aqueous based process which has been scaled to cGMP
  • Preservation of biological activity has been shown in man
  • 14:20 SMALL IS BEAUTIFUL

    Dr Julian Blair

    Dr Julian Blair, Research Director, Quadrant Healthcare

  • Microencapsulation technologies
  • Applications in drug delivery
  • Mechanisms to control drug release
  • Microparticle preparation
  • Development of oligosaccharide based matrices as novel drug delivery systems
  • 15:00 CHALLENGING THE NOTION OF DRUG DELIVERY

    Dr Paul Ashton

    Dr Paul Ashton, President & Chief Executive Officer, Control Delivery Systems

  • Local sustained delivery of small molecules
  • Drug delivery to difficult to reach sites
  • Novel drug delivery technologies
  • Clinical developments
  • Preclinical developments
  • 15:40 Afternoon Tea

    16:00 IMPROVING DRUG SOLUBILITY AND AVAILABILITY

    Dr Leonardo Rabaglia

    Dr Leonardo Rabaglia, Director, Research & Development (Europe), Eurand International

  • Drug solubilisation techniques: an overview
  • Carriers and excipients for poorly soluble drug formulations
  • Production of activated systems: liquid versus solid state technologies
  • Activated systems characterisation: physicochemical methodologies & drug release kinetics
  • Preclinical ‘in vivo’ testing (animal model)
  • Case Study: BioriseTM technology platform
  • 16:40 DRUG PROFILES

    Dr Ian Wilding

    Dr Ian Wilding, Chief Executive, Pharmaceutical Profiles

  • Understanding human gastrointestinal physiology: the key to successful oral CR development
  • Human absorption studies to provide a route map for product development
  • Preclinical versus human absorption data
  • Permeability versus dissolution dependent bioavailability
  • Pk/pd relationship in oral CR development; an FDA perspective
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Professor David Ganderton

    Professor David Ganderton, Consultant, Vectura

    9:10 ELECTROSTATIC POWDER DEPOSITION

    Dr Marshall Whiteman

    Dr Marshall Whiteman, Director, Science & Technology, Phoqus

  • Basic principles
  • Dose loading
  • Fast dissolving tablets
  • Oral modified release systems
  • Intellectual property
  • 9:40 ORAL DELIVERY – THE PATIENT’S CHOICE

    Dr Iain Cumming

    Dr Iain Cumming, Vice President, New Technology Development, Elan

  • Multiparticulate systems
  • Single component - matrix drug absorption system
  • Multiple component – multiple release drug absorption system
  • Tailored release profiles
  • Polymer coating systems
  • Convenience dosage forms
  • 10:20 PREDICTABLE ER, SAFE AND SHORT ROUTE TO THE MARKET

    Dr Peter Fyhr

    Dr Peter Fyhr, Research & Development, Director, Amarin Development

  • Attrition in pharmaceutical development
  • Predictable models in vitro and in vivo
  • An IVIV predictable coating, the DCV
  • 11:00 Morning Coffee

    11:20 NEEDLE FREE DELIVERY

    Mr Khawar Mann

    Mr Khawar Mann, Director, Business Development, Weston Medical

  • Pre-filled, single use and disposable needle free drug delivery
  • Clinical compliance
  • Patience preference
  • High level market differentiation
  • 12:00 TRANSDERMAL DELIVERY

    Dr Suresh Borsadia

    Dr Suresh Borsadia, Vice President, Research & Development, Lavipharm Laboratories

  • Skin permeability and diffusion fundamentals
  • Advantages and disadvantages of transdermal delivery
  • Technological advancements and their impact
  • Transdermal delivery in acute & chronic therapy
  • Challenges & solutions in the years ahead
  • 12:40 Networking Lunch

    13:40 SUSTAINED RELEASE INJECTABLE PRODUCTS

    Dr Alessandro Martini

    Dr Alessandro Martini, Director, New Drug Delivery Systems, Pharmacia

  • Rationale for sustained release injectable products
  • Design controlled release parenteral dosage forms
  • Select the right technology (contrast and compare)
  • Parallel evaluation of multiple technologies (internal and external)
  • Unmet needs and future challenges
  • 14:20 IMPROVING GENE TRANSFER TECHNOLOGIES

    Dr Alain Rolland

    Dr Alain Rolland, Senior Vice President, Preclinical Research & Development, Valentis

  • Gene delivery systems
  • Controlled release plasmid delivery
  • Cationic lipid systems and non-condensing polymers as gene delivery systems
  • Gene therapies for local and systemic applications
  • Gene regulation and future developments
  • 15:00 CHOOSING THE RIGHT CONTROLLED RELEASE TECHNOLOGY FOR YOUR DRUG

    Dr Paul Gellert

    Dr Paul Gellert, Principal Scientist, Manager, Drug Delivery & Patent Co-ordinator, AstraZeneca

  • Profiling drug candidates
  • Characterisation of the delivery problem
  • Identifying controlled release delivery systems
  • Potential technical issues
  • Establishing collaborations with drug delivery companies
  • Pitfalls to avoid in establishing successful partnerships
  • 15:40 Afternoon Tea

    16:00 UNITING FORCES

    Dr Jane Worlock

    Dr Jane Worlock, Vice President, Business Development, SkyePharma

  • Ingredients for successful alliances
  • Benchmarks for partner selection
  • Collaborative product development
  • Focus on bottlenecks
  • Case study: TBA
  • Future directions for collaborative development partnerships
  • 16:40 REGULATORY ISSUES

    Dr Michael Robertson

    Dr Michael Robertson, Director, European Regulatory Affairs, Pharmaceutical Quality Matters

  • Regulatory overview: requirements and issues
  • Controlled release versus conventional release
  • Legislation, pharmacopoeias, guidelines
  • The chemistry and pharmacy (part II) dossier
  • The pharmaceutical expert report
  • The pharmaceutical assessment
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.